Sigma Planning Corp Raises Stock Holdings in Brainsway Ltd. Sponsored ADR $BWAY

Sigma Planning Corp grew its stake in shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) by 369.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 70,363 shares of the company’s stock after acquiring an additional 55,363 shares during the quarter. Sigma Planning Corp owned about 0.18% of Brainsway worth $935,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Y.D. More Investments Ltd raised its stake in Brainsway by 136.6% during the 1st quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock valued at $3,615,000 after buying an additional 157,042 shares during the last quarter. ARK Investment Management LLC purchased a new position in Brainsway in the fourth quarter worth about $2,422,000. UBS Group AG boosted its position in Brainsway by 2,028.6% in the third quarter. UBS Group AG now owns 63,878 shares of the company’s stock worth $963,000 after purchasing an additional 60,877 shares during the last quarter. Two Sigma Investments LP boosted its position in Brainsway by 25.2% in the third quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock worth $1,551,000 after purchasing an additional 20,706 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of Brainsway during the 1st quarter valued at about $232,000. 30.11% of the stock is currently owned by institutional investors.

Brainsway Stock Performance

NASDAQ:BWAY opened at $15.73 on Friday. The stock has a 50-day simple moving average of $15.01 and a two-hundred day simple moving average of $13.71. Brainsway Ltd. Sponsored ADR has a 52-week low of $5.68 and a 52-week high of $17.35. The firm has a market capitalization of $631.24 million, a PE ratio of 44.94 and a beta of 1.22.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings data on Wednesday, May 13th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.05 by $0.07. Brainsway had a return on equity of 12.28% and a net margin of 15.68%.The firm had revenue of $15.53 million for the quarter, compared to the consensus estimate of $14.63 million. Equities analysts forecast that Brainsway Ltd. Sponsored ADR will post 0.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on BWAY. Zacks Research upgraded shares of Brainsway from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Brainsway in a research report on Friday. Weiss Ratings raised shares of Brainsway from a “hold (c)” rating to a “buy (b-)” rating in a report on Friday, April 24th. Finally, Wall Street Zen upgraded shares of Brainsway from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $14.50.

Brainsway Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.